Skip to main content
. 2024 Jun 22;15(6):440. doi: 10.1038/s41419-024-06822-3

Fig. 5. Local administration of fasudil and sFasL suppresses U87 glioblastoma growth in vivo.

Fig. 5

a Tumor sizes in fasudil+sFasL treatment arm was significantly smaller than those in any other group at the end of the treatment. Panels on the right show the tumor sizes (mean ± sd) measured on 19- and 26-days post-implantation (***p < 0.001, **p < 0.01, and *p < 0.05; ordinary one-way ANOVA). b The survival probability in the fasudil+sFasL group was significantly higher than that in any other group [log-rank (Mantel‒Cox) test; compared to the combination group: PBS p = 0.022, fasudil p = 0.006, and sFasL p = 0.048]. c Extracted tumors one month after implantation. The tumor in one of the mice in the fasudil+sFasL combination group was completely eliminated.